Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

Rhea-AI Summary

Hemogenyx Pharmaceuticals (OTC: HOPHF) announced an update on the admission of new ordinary shares. The FCA has scheduled the admission hearing for 5 January 2026, with admission expected on or around 6 January 2026 at 08:00.

All other details from the company’s 18 December 2025 announcement remain unchanged.

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.

The FCA has notified the Company that the admission hearing has been scheduled for the earliest available date being 5 January 2026, with admission expected to occur on or around 8.00 a.m. on 6 January 2026.

All other details outlined in the Company's announcement of 18 December 2025 remain unchanged.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
AlbR Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

When is Hemogenyx (HOPHF) scheduled for the FCA admission hearing?

The FCA admission hearing is scheduled for 5 January 2026.

When are Hemogenyx (HOPHF) new ordinary shares expected to be admitted to trading?

Admission of the new ordinary shares is expected on or around 6 January 2026 at 08:00.

Does the 22 December 2025 Hemogenyx (HOPHF) update change the 18 December 2025 announcement?

No; the update states that all other details remain unchanged from the 18 December 2025 announcement.

How can investors get more information about Hemogenyx (HOPHF) admission timings?

Investors can contact the company via the provided investor contacts or monitor regulatory news for any further updates.

What markets and subsidiaries are referenced in Hemogenyx (HOPHF) company information?

The company is listed on the London Stock Exchange under HEMO and operates US subsidiaries Hemogenyx Pharmaceuticals LLC and Immugenyx LLC in New York City.